Bartlett & CO. Wealth Management LLC Cuts Stake in Thermo Fisher Scientific Inc. $TMO

Bartlett & CO. Wealth Management LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.9% during the first quarter, HoldingsChannel reports. The firm owned 182,938 shares of the medical research company’s stock after selling 11,431 shares during the period. Thermo Fisher Scientific accounts for 1.1% of Bartlett & CO. Wealth Management LLC’s portfolio, making the stock its 26th largest position. Bartlett & CO. Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $84,627,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. High Note Wealth LLC lifted its position in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $28,000. JPL Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $29,000. Finally, Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO opened at $532.17 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a 1-year low of $403.36 and a 1-year high of $643.99. The company has a 50-day moving average of $484.57 and a 200-day moving average of $514.88. The company has a market capitalization of $197.77 billion, a P/E ratio of 29.26, a PEG ratio of 2.41 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same period last year, the firm earned $5.15 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on TMO shares. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective on the stock. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $602.14.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.